Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Capital Expenditures (2019 - 2025)

Eton Pharmaceuticals' Capital Expenditures history spans 6 years, with the latest figure at $284000.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures changed N/A year-over-year to $284000.0; the TTM value through Sep 2025 reached $296000.0, up 2014.29%, while the annual FY2024 figure was $26000.0, N/A changed from the prior year.
  • Capital Expenditures for Q3 2025 was $284000.0 at Eton Pharmaceuticals, up from $12000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $284000.0 in Q3 2025 and bottomed at $2000.0 in Q3 2021.
  • The 4-year median for Capital Expenditures is $12000.0 (2022), against an average of $44250.0.
  • The largest annual shift saw Capital Expenditures plummeted 90.91% in 2021 before it soared 200.0% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $4000.0 in 2021, then skyrocketed by 200.0% to $12000.0 in 2022, then changed by 0.0% to $12000.0 in 2024, then soared by 2266.67% to $284000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Capital Expenditures are $284000.0 (Q3 2025), $12000.0 (Q4 2024), and $14000.0 (Q1 2024).